‘What has been an issue with this stock is there has been people who have wanted to get out of this stock’GROWING Queensland biotechnology group Peplin is shifting its parent company to the US, contrasting with statements a year ago to remain an Australian company.But Peplin, developing a skin cancer drug derived from weed sap, insists it will retain operations in Australia and local shareholders will still hold stock.
